Skip to content
Clinical Trials – home

Find therapies in clinical trials near you – page 849

recruiting
3 987
countries
28
conditions
2 109

10 381 trials match your criteria

Study of Venetoclax in Chronic Myeloid Leukemia Patients After Stopping Tyrosine Kinase Inhibitor Treatment

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Venetoclax

Study on the Effectiveness of Vidofludimus Calcium (IMU-838) in Adults with Relapsing Multiple Sclerosis

Investigational
Countries:BulgariaBulgaria
  • Participants:18–64 years
  • Substances:Vidofludimus Calcium

Adrenal adenoma

Not recruiting

Study on Metyrapone for Patients with Mild Autonomous Cortisol Secretion Due to Adrenal Adenoma

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Metyrapone Bp

Dermatitis atopic

Not recruiting

Study on Nemolizumab for Children Aged 2-11 with Moderate-to-Severe Atopic Dermatitis Not Controlled by Topical Treatments

InvestigationalNo placebo
Countries:HungaryHungary
  • Participants:0–17 years
  • Substances:Nemolizumab

Face lift

Not recruiting

Study on the Effects of Botulinum Toxin Type A for Treating Moderate to Severe Forehead Lines in Adults

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Botulinum Toxin Type A

Germ cell cancer

Not recruiting

Study Comparing Carboplatin and Cisplatin for Patients with Extracranial Malignant Germ Cell Tumors

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:0–17 years · 18–64 years
  • Substances:Carboplatin

Endometrial cancer+2

Not recruiting

Study on Selinexor as Maintenance Therapy for Patients with Advanced or Recurrent Endometrial Cancer After Chemotherapy

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Selinexor

Malignant melanoma

Not recruiting

Study Comparing High Dose Interferon, Ipilimumab, and Pembrolizumab for Patients with High Risk Resected Melanoma

Registered drugNo placebo
Countries:IrelandIreland
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab

Peritoneal sarcoma+2

Not recruiting

Study of mirvetuximab soravtansine compared to standard chemotherapy in women with platinum-resistant advanced ovarian cancer with high folate receptor expression

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Paclitaxel

Study comparing trifluridine/tipiracil with bevacizumab versus capecitabine with bevacizumab as first-line treatment for patients with metastatic colorectal cancer who cannot receive intensive therapy

Registered drugNo placebo
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab

Study on Degenerative Disc Disease: Effects of Autologous Adipose-Derived Mesenchymal Stem Cells in Patients with Degenerative Disc Disease

InvestigationalNo placebo
Countries:DenmarkDenmark
  • Participants:18–64 years
  • Substances:Autologous Adipose-Derived Mesenchymal Stem Cells In Vitro Expanded

Study Comparing Subcutaneous and Intravenous Human Normal Immunoglobulin for New Patients with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

Registered drugNo placebo
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:Human Normal Immunoglobulin
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.